RAD51D’s loss-of-function mutation is an inclusion criterion for trials evaluating the effectiveness of Rucaparib in ovarian cancer [30] or prostate cancer [31], Talazoparib in HER2-negative BC [32], and Niraparib in pancreatic cancer [33]. This evidence concerns the gene RAD51D and breast cancer.